Pipeline

Fueled by a deep scientific expertise built over decades of research, Prothena is integrating scientific insights around protein dysregulation to advance a pipeline of therapeutic candidates for a number of neurodegenerative and rare peripheral amyloid diseases which affect millions of people and their families worldwide.

Prothena’s wholly owned programs include birtamimab for the potential treatment of AL amyloidosis and a portfolio of programs for the potential treatment of Alzheimer’s disease including PRX012 that targets Aβ (amyloid beta) and PRX123, the company’s dual Aβ-tau vaccine. Prothena’s collaborations include prasinezumab, which targets alpha-synuclein, with Roche for the potential treatment of Parkinson’s disease; NNC6019/PRX004 for the potential treatment of ATTR amyloidosis with Novo Nordisk; and programs that target tau (BMS-986446/PRX005), TDP-43, and an undisclosed target (PRX019) with Bristol Myers Squibb for the potential treatment of neurodegenerative diseases.

Program/Indication

Protein Target

Discovery

Preclinical

Phase 1

Phase 2

Phase 3

Commercial Rights

Program/Indication

BirtamimabAL Amyloidosis

Protein Target

Kappa &
Lambda Light Chain

Phase 3 Phase 2 Phase 1 Preclinical Discovery
Commercial Rights
Program/Indication

PrasinezumabParkinson’s Disease

Protein Target

α-Synuclein
(C-terminus)

Phase 3 Phase 2 Phase 1 Preclinical Discovery
Commercial Rights
roche logo
Program/Indication

NNC6019/PRX004ATTR Amyloidosis

Protein Target

Transthyretin
(misTTR)

Phase 3 Phase 2 Phase 1 Preclinical Discovery
Commercial Rights
Novo Nordisk Logo
Program/Indication

BMS-986446/PRX005Alzheimer’s Disease

Protein Target

Tau (MTBR)

Phase 3 Phase 2 Phase 1 Preclinical Discovery

Phase 1 clinical trial

Commercial Rights
bristol myers squibb logo
Program/Indication

PRX012Alzheimer’s Disease

Protein Target

Aβ (N-terminus)

Phase 3 Phase 2 Phase 1 Preclinical Discovery
Commercial Rights
Program/Indication

PRX123Alzheimer’s Disease

Protein Target

Aβ + Tau

Phase 3 Phase 2 Phase 1 Preclinical Discovery

IND cleared

Commercial Rights
Program/Indication

PRX019Neurodegeneration

Protein Target

Undisclosed Target

Phase 3 Phase 2 Phase 1 Preclinical Discovery

IND cleared

Commercial Rights
bristol myers squibb logo
Program/Indication

TDP-43ALS

Protein Target

TDP-43

Phase 3 Phase 2 Phase 1 Preclinical Discovery
Commercial Rights
bristol myers squibb logo
Program/Indication

UndisclosedAD in Down Syndrome

Protein Target

Undisclosed Target

Phase 3 Phase 2 Phase 1 Preclinical Discovery
Commercial Rights

¹ Primary endpoint of all-cause mortality at a significance level of 0.10 under the Special Protocol Assessment (SPA) agreement with FDA; Aβ,Abeta; AD, Alzheimer’s disease; ALS, amyotrophic lateral sclerosis; mAb, monoclonal antibody

mAb

Small Molecule

Vaccine

Undisclosed